期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 85, 期 -, 页码 44-56出版社
ELSEVIER
DOI: 10.1016/j.addr.2014.10.011
关键词
Anti-infectives; Tuberculosis; Pneumonia; Cystic fibrosis; Cell culture models; Disease-relevant models; Alternatives to animal testing; 3R principle; Calu-3; A549
资金
- German Federal Ministry of Education [13N11458, 13N12530]
New pharmaceutical formulations must be proven as safe and effective before entering clinical trials. Also in-the context of pulmonary drug delivery, preclinical models allow testing of novel antimicrobials, reducing risks and costs during their development. Such models allow reducing the complexity of the human lung, but still need to reflect relevant (patho-) physiological features. This review focuses on preclinical pulmonary models, mainly in vitro models, to assess drug safety and efficacy of antimicrobials. Furthermore, approaches to investigate common infectious diseases of the respiratory tract, are emphasized. Pneumonia, tuberculosis and infections occurring due to cystic fibrosis are in focus of this review. We conclude that especially in vitro models offer the chance of an efficient and detailed analysis of new antimicrobials, but also draw attention to the advantages and limitations of such currently available models and critically discuss the necessary steps for their future development. (C) 2014 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据